Linuo Pharmaceutical Packaging CEO Sun Pengfei Issues 2026 New Year Message
As 2026 approaches, Mr. Sun Pengfei, CEO and General Manager of Linuo Pharmaceutical Packaging, released the company’s New Year message, reflecting on key achievements in 2025 and outlining strategic priorities for the next stage of development.
In 2025, marking the 30th anniversary of the company, Linuo Pharmaceutical Packaging actively responded to global economic and industrial restructuring by reinforcing its core pharmaceutical packaging business and accelerating innovation across intelligent manufacturing, global operations, and sustainable growth.
Strategic Focus on Core Pharmaceutical Packaging
Linuo Pharmaceutical Packaging continued to strengthen its core competitiveness in pharmaceutical glass packaging. In 2025, the second furnace of the Type I lightweight molded pharmaceutical glass bottle industrialization project was successfully commissioned, further consolidating capacity advantages in high-end pharmaceutical containers.
At the same time, products such as dual-chamber cartridges, PFS, and RTU packaging solutions entered a new phase of intelligent factory construction and global launch, signaling the company’s transition from technology follower to standard-setter within the industry.
Intelligent Manufacturing Driving Quality and Efficiency
Intelligent manufacturing remained a key driver of operational improvement. During the year, Linuo Pharmaceutical Packaging integrated over 420,000 high-quality industrial data assets into standardized data management systems, enabling more precise and efficient production control.
The company also achieved CMMM Level 4 certification, placing it among industry leaders in digital manufacturing maturity and bringing it closer to its goal of becoming a global lighthouse factory in pharmaceutical packaging. Leveraging deep expertise in high-temperature manufacturing environments, its wholly owned subsidiary Shandong Linuo Intelligent Robotics Co., Ltd. began commercializing intelligent solutions, forming a new growth engine.
Advancing Global Collaboration and Localized Operations
In 2025, Linuo Pharmaceutical Packaging entered a new stage of globalization focused on local integration and ecosystem collaboration. Domestically, the acquisition of equity in Suzhou Chuangyang New Materials expanded plastic packaging capabilities, enabling a one-stop “glass + plastic” pharmaceutical packaging solution.
Internationally, strategic cooperation with companies such as Brazil’s SANTISA and U.S.-based Xseer strengthened localized service capacity and risk resilience, accelerating the shift from “Made in China” to global operations.
Brand and Technology Upgrades in Parallel
The company also promoted the transformation of its heat-resistant glass business toward proprietary branding, launching LEBOLEBO in the domestic market and BOROHOUSE overseas. In parallel, Linuo Pharmaceutical Packaging established a CNAS-accredited testing and research center through university–industry collaboration, reinforcing technical foundations and supporting participation in industry standard development.
(For reference, CNAS accreditation standards can be found on the official China National Accreditation Service platform: https://www.cnas.org.cn)
Looking Ahead to 2026
2026 marks the beginning of China’s new “15th Five-Year Plan” period. With three decades of industry expertise, a clear strategic roadmap, and strengthened intelligent manufacturing and global networks, Linuo Pharmaceutical Packaging is confident in achieving resilient, long-term growth and continuing to serve global pharmaceutical customers with high-quality packaging solutions.
Learn more about Linuo Pharmaceutical Packaging and its product portfolio at:
👉 Internal link: https://www.linuo-pharma.com
